Abstract
Several studies have demonstrated that the high expression of programmed death-ligand-1 (PD-L1) can predict the low overall response rate (ORR) rates in advanced non-small cell lung cancer patients (NSCLCs) with epidermal growth factor receptor (EGFR) mutation treated with TKI therapy. But the role of PD-L1 expression in the completely resected NSCLCs with EGFR mutation is still controversial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
